Anticancer Agent 83, a potent inhibitor of LOX IMVI cell growth, demonstrates anticancer efficacy with a GI50 value of 0.15 mM. It disrupts mitochondrial membrane potential and induces DNA damage, thereby promoting apoptosis in leukemia cells [1].

Anticancer agent 83 (compound 4a) (0.01-100 μM; 24 h) showing strong activity towards human colon carcinoma HCT116 p53 / cells with deletion of P53 gene (GI 50 =8.4 μM), human epidermoid cervix carcinoma KB3-1 (GI 50 =7.4 μM), human ovarian carcinoma Skov 3 cells (GI 50 =10 μM), and human chronic myelogenous leukemia K562 cells (GI 50 =5.4 μM) [1]. Anticancer agent 83 (0.5 μM; 24 h) interrupts DNA stability and induction of apoptosis in Jurkat cells, and decreases mitochondrial membrane potential [1]. Cell Viability Assay [1] Cell Line: Human colon carcinoma HCT116 p53 / cells with deletion of P53 gene, human epidermoid cervix carcinoma KB3-1, human ovarian carcinoma Skov 3 cells, and human chronic myelogenous leukemia K562 cells Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time: 24 hours Result: Inhibited cell viability in different cells with GI 50 s of 8.4 M (HCT116 p53 / ), 7.4 M (KB3-1), 10 M (Skov 3), and 5.4 M (K562), respectively. Immunofluorescence [1] Cell Line: Jurkat cells Concentration: 0.5 μM Incubation Time: 24 hours Result: Induced morphological changes (including apoptotic bodies, membrane blebbing, chromatin condensation), and DNA fragmentation in Jurkat T-cells.